RxDoctor Payments Data

Rachelle Usis

Family · Tucson, AZNPI 1871914374

Payments from drug & device makers

$3,918in general payments, 2019–2025

Across 225 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$963
  • Pfizer$439
  • GSK$438
  • AbbVie$422
  • Novo Nordisk$303
  • Amgen$149
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,918 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$106,162
Medicare patients
161
Services billed
906

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$63,547
OzempicSemaglutide15$19,753
JanuviaSitagliptin Phosphate16$19,459
FarxigaDapagliflozin Propanediol12$17,939
Breo ElliptaFluticasone/Vilanterol12$4,623
SymbicortBudesonide/Formoterol Fumarate17$3,960
Omeprazole71$1,980
Levemir FlexpenInsulin Detemir11$1,809
Atorvastatin Calcium192$1,774
Telmisartan38$1,631
Gabapentin69$1,510
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,337
Amlodipine Besylate220$1,301
Albuterol Sulfate HfaAlbuterol Sulfate59$1,218
Levothyroxine Sodium155$1,196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$104$63,54740 claims
AstraZenecaFarxiga, Symbicort$963$21,89929 claims
Novo NordiskOzempic$303$19,75315 claims
MerckJanuvia$124$19,45916 claims
GSKBreo Ellipta$438$4,62312 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$31$1,196155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →